
An intensive residency for leaders leveraging China's clinical velocity and institutional partnerships to pressure-test and scale the future of Women's Health worldwide.
Who it is for
We are seeking a specific cohort of visionary Women's Health innovators. This programme is designed for founders who recognise that China is no longer a 'future' market, but a global center for clinical speed and manufacturing excellence early on.
Ideal Candidates are:
(Early-stage and Growth-stage companies are both welcome)
Why Apply
Serious engagement in China requires more than interest; it requires sovereign context and institutional trust.
This programme is a four-day surgical entry into the ecosystem. You will move past the gatekeepers to engage directly with decision-makers from Bayer, GE HealthCare, BD Medical, Raffles Hospital and more to come!
The Goal: To help you identify exactly where your innovation fits within the Chinese clinical and corporate landscape, and to build the high-level rapport that translates back to your home market and global headquarters.
Why is the programme selective?
To ensure the integrity of our closed-door sessions and the 1:1 ratio of investors to founders, this is an application-based programme. Our two-stage interview process ensures a mutual fit. We are not building a crowd; we are curating a high-performance group of leaders for whom this access will yield genuine, long-term strategic progress.
How It Works
Complete the application form below with your company details and China objectives.
Shortlisted applicants will be invited for an intro call to discuss objectives and fit.
Selected participants confirm their spot with the programme fee (GBP 1,999).
Select from suggestions or type a custom value and press Enter
Select from suggestions or type a custom value and press Enter